Measured by its ability to inhibit the biological activity of IGFII on MCF7 human breast adenocarcinoma cells. The EC50 for this effect is 15-25 ng/mL in the presence of 14 ng/mL human IGFII.
Product Details
Product Details
Product Specification
| Species | Mouse |
| Synonyms | Insulin-like growth factor-binding protein 1, IBP-1, IGF-binding protein 1, IGFBP-1 |
| Accession | P47876 |
| Amino Acid Sequence | Ala26-Asn272 with His Tag at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 35-38 kDa (Reducing) |
| Purity | >95% by SDS-PAGE, >90% by HPLC. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, 1mM EDTA, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Nat Med. 2024 Jun;30(6):1689-1695. |
Background
Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) is a 25–30 kDa secreted protein encoded by the Igfbp1 gene, predominantly expressed in the liver, decidua, and kidneys. As a critical regulator of the IGF axis, IGFBP-1 binds IGF-I and IGF-II with high affinity (Kd ~10⁻¹⁰ M), thereby modulating ligand bioavailability, half-life, and receptor interactions.
IGFBP-1 in mouse models represents a critical nexus between growth regulation and metabolic homeostasis, with applications spanning developmental biology, metabolic disease modeling, cancer resistance mechanisms, and cardiovascular protection. Industrial applications focus on biomarker assay development, RGD-based peptide therapeutics, and combination strategies to overcome cancer drug resistance.
Picture
Picture
Bioactivity
SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
RP-HPLC
>90% as determined by RP-HPLC.
